Adenosine A2B receptor antagonist suppresses differentiation to regulatory T cells without suppressing activation of T cells

Biochemical and Biophysical Research Communications

Volumn 409, Issue 1, 2011, Pages 114-119

  Nakatsukasa, Hiroko ^a   Tsukimoto, Mitsutoshi ^a   Harada, Hitoshi ^b   Kojima, Shuji ^a  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

^b SUZUKA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

A1 receptor; A2B receptor; Adenosine; Foxp3; Regulatory T cell; T cell differentiation

Indexed keywords

5 AMINO 2 (2 FURYL) 7 [3 (4 METHOXYPHENYL)PROPYL]PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A2B RECEPTOR ANTAGONIST; ADENOSINE A3 RECEPTOR; BIOCHEMICAL MARKER; CD4 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; MRS 3777; PADGEM PROTEIN; PSB 36; PSB 603; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CYTOKINE PRODUCTION; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; ANIMAL; BAGG ALBINO MOUSE; CELL DIFFERENTIATION; CYTOLOGY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; NEOPLASM; PHYSIOLOGY;

MURINAE;

ADENOSINE A1 RECEPTOR ANTAGONISTS; ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; CELL DIFFERENTIATION; FORKHEAD TRANSCRIPTION FACTORS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2B; T-LYMPHOCYTES, REGULATORY;

EID: 79956191026     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.04.125     Document Type: Article

References (33)

1. Haag F., Adriouch S., Braß A., Jung C., Möller S., Scheuplein F., Bannas P., Seman M., Koch-Nolte F. Extracellular NAD and ATP: partners in immune cell modulation. Purinergic Signal. 2007, 3:71-81.
2. Kumar V., Sharma A. Adenosine: an endogenous modulator of innate immune system with therapeutic potential. Eur. J. Pharmacol. 2009, 616:7-15.
3. Weber F.C., Esser P.R., Muller T., Ganesan J., Pellegatti P., Simon M.M., Zeiser R., Idzko M., Jakob T., Martin S.F. Lack of the purinergic receptor P2X(7) results in resistance to contact hypersensitivity. J. Exp. Med. 2010, 207:2609-2619.
4. Schenk U., Westendorf A.M., Radaelli E., Casati A., Ferro M., Fumagalli M., Verderio C., Buer J., Scanziani E., Grassi F. Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. Sci. Signal. 2008, 1:ra6.
5. Yip L., Woehrle T., Corriden R., Hirsh M., Chen Y., Inoue Y., Ferrari V., Insel P.A., Junger W.G. Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. FASEB J. 2009, 23:1685-1693.
6. Tsukimoto M., Tokunaga A., Harada H., Kojima S. Blockade of murine T cell activation by antagonists of P2Y6 and P2X7 receptors. Biochem. Biophys. Res. Commun. 2009, 384:512-518.
7. Tokunaga A., Tsukimoto M., Harada H., Moriyama Y., Kojima S. Involvement of SLC17A9-dependent vesicular exocytosis in the mechanism of ATP release during T cell activation. J. Biol. Chem. 2010, 285:17406-17416.
8. Yegutkin G.G. Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim. Biophys. Acta 2008, 1783:673-694.
9. Haskó G., Linden J., Cronstein B., Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug Discov. 2008, 9:759-770.
10. Ernst P.B., Garrison J.C., Thompson L.F. Much ado about adenosine: adenosine synthesis and function in regulatory T cell biology. J. Immunol. 2010, 185:1993-1998.
11. Haskó G., Csóka B., Németh Z.H., Vizi E.S., Pacher P. A(2B) adenosine receptors in immunity and inflammation. Trends Immunol. 2009, 30:263-270.
12. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone. I: Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 1986, 136:2348-2357.
13. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., Weiner H.L., Kuchroo V.K. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
14. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGF-β in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
15. Dardalhon V., Awasthi A., Kwon H., Galileos G., Gao W., Sobel R.A., Mitsdoerffer M., Strom T.B., Elyaman W., Ho I.C., Khoury S., Oukka M., Kuchroo V.K. IL-4 inhibits TGF-β-induced Foxp3+ T cells and, together with TGF-β, generates IL-9+IL-10+Foxp3- effector T cells. Nat. Immunol. 2008, 9:1347-1355.
16. Veldhoen M., Uyttenhove C., Snick J.V., Helmby H., Westendorf A., Buer J., Martin B., Wilhelm C., Stockinger B. Transforming growth factor-β " reprograms" the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat. Immunol. 2008, 9:1341-1346.
17. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995, 155:1151-1164.
18. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1106.
19. Battaglia M., Gregori S., Bacchetta R., Roncarolo M.G. Tr1 cells: from discovery to their clinical application. Semin. Immunol. 2006, 18:120-127.
20. Taylor P.A., Noelle R.J., Blazar B.R. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J. Exp. Med. 2001, 193:1311-1318.
21. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 2003, 4:330-336.
22. Sojka D.K., Huang Y.H., Fowell D.J. Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target. Immunology 2008, 124:13-22.
23. Sakaguchi S., Wing K., Onishi Y., Prieto-Martin P., Yamaguchi T. Regulatory T cells: how do they suppress immune responses?. Int. Immunol. 2009, 21:1105-1111.
24. Nelson B.H. IL-2, regulatory T cells, and tolerance. J. Immunol. 2004, 172:3983-3988.
25. Chen W., Jin W., Hardegen N., Lei K.J., Li L., Marinos N., McGrady G., Wahl S.M. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 2003, 198:1875-1886.
26. Atarashi K., Nishimura J., Shima T., Umesaki Y., Yamamoto M., Onoue M., Yagita H., Ishii N., Evans R., Honda K., Takeda K. ATP drives lamina propria T(H)17 cell differentiation. Nature 2008, 455:808-812.
27. Corriden R., Insel P.A., Junger W.G. A novel method using fluorescence microscopy for real-time assessment of ATP release from individual cells. Am. J. Physiol. Cell Physiol. 2007, 293:1420-1425.
28. de la Rosa M., Rutz S., Dorninger H., Scheffold A. Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur. J. Immunol. 2004, 34:2480-2488.
29. Pandiyan P., Zheng L., Ishihara S., Reed J., Lenardo M.J. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat. Immunol. 2007, 8:1353-1362.
30. Sauer S., Bruno L., Hertweck A., Finlay D., Leleu M., Spivakov M., Knight Z.A., Cobb B.S., Cantrell D., O'Connor E., Shokat K.M., Fisher A.G., Merkenschlager M. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc. Natl. Acad. Sci. USA 2008, 105:7797-7802.
31. Ohkura N., Sakaguchi S. Regulatory T cells: roles of T cell receptor for their development and function. Semin. Immunopathol. 2010, 32:95-106.
32. Lewis R.S. Calcium signaling mechanisms in T lymphocytes. Annu. Rev. Immunol. 2001, 19:497-521.
33. Nishikawa H., Sakaguchi S. Regulatory T cells in tumor immunity. Int. J. Cancer 2010, 127:759-767.